CN117447393A - 一种瑞马唑仑中间体的制备方法 - Google Patents
一种瑞马唑仑中间体的制备方法 Download PDFInfo
- Publication number
- CN117447393A CN117447393A CN202311400526.4A CN202311400526A CN117447393A CN 117447393 A CN117447393 A CN 117447393A CN 202311400526 A CN202311400526 A CN 202311400526A CN 117447393 A CN117447393 A CN 117447393A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- reaction
- preparation
- compound shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 238000006243 chemical reaction Methods 0.000 claims abstract description 57
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 238000004090 dissolution Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- -1 chloro, bromo, iodo, methyl Chemical group 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000012544 monitoring process Methods 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 230000000171 quenching effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 9
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 8
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- SURKZMFXICWLHU-UHFFFAOYSA-N 2-bromo-4-chloropyridine Chemical compound ClC1=CC=NC(Br)=C1 SURKZMFXICWLHU-UHFFFAOYSA-N 0.000 description 4
- VAJCSPZKMVQIAP-UHFFFAOYSA-N 5-methyl-1h-indole-2,3-dione Chemical compound CC1=CC=C2NC(=O)C(=O)C2=C1 VAJCSPZKMVQIAP-UHFFFAOYSA-N 0.000 description 4
- WEWXXYDHYCDEKY-UHFFFAOYSA-N (2-aminophenyl)-pyridin-2-ylmethanone Chemical class NC1=CC=CC=C1C(=O)C1=CC=CC=N1 WEWXXYDHYCDEKY-UHFFFAOYSA-N 0.000 description 3
- JFYFMQYIWHLYOH-UHFFFAOYSA-N OC1(C(NC2=CC=CC=C12)=O)C1=NC=CC=C1 Chemical compound OC1(C(NC2=CC=CC=C12)=O)C1=NC=CC=C1 JFYFMQYIWHLYOH-UHFFFAOYSA-N 0.000 description 3
- MBVCESWADCIXJN-UHFFFAOYSA-N 5-Bromoisatin Chemical compound BrC1=CC=C2NC(=O)C(=O)C2=C1 MBVCESWADCIXJN-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- KHVZPFKJBLTYCC-UHFFFAOYSA-N (2-amino-5-bromophenyl)-pyridin-2-ylmethanone Chemical compound NC1=CC=C(Br)C=C1C(=O)C1=CC=CC=N1 KHVZPFKJBLTYCC-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明属于医药化合物合成技术领域,具体公开了一种瑞马唑仑中间体的制备方法。本发明的制备方法通过将式A所示化合物与式Ⅱ所示化合物混合反应,得到式B所示化合物;所述式B所示化合物加入溶剂中溶解,之后加碱,反应制得式C所示化合物。本发明提供的瑞马唑仑中间体的制备方法,合成路线简短,原料便宜,操作简单,易于工业化生产,且制得的目标化合物纯度高。
Description
技术领域
本发明涉及医药化合物合成技术领域,具体涉及一种瑞马唑仑中间体的制备方法。
背景技术
瑞马唑仑是由英国葛兰素史克(gsk)设计,后由德国paion公司开发的一种超速效的镇静、麻醉用药。瑞马唑仑属于苯二氮卓类麻醉药物,作用于GABAA受体,可抑制兴奋性神经元,主要用于手术中的全身麻醉。与同类产品相比,瑞马唑仑具有起效迅速、苏醒快、对呼吸/循环抑制作用较低、有特异性拮抗剂等临床优势,其在安全性、稳定性等方面的优势已被全球多家药企认可,未来将具有巨大的市场前景。
2-(2-氨基-苯甲酰基)吡啶类化合物是瑞马唑仑制备的关键中间体之一。本发明旨在提供一种2-(2-氨基-苯甲酰基)吡啶类化合物的制备方法,以推动该类化合物的工业化生产。
发明内容
本发明主要解决的技术问题是提供一种瑞马唑仑中间体的制备方法,该制备方法合成路线简短,原料便宜,操作简单,易于工业化生产,且制得的目标化合物纯度高。
为解决上述技术问题,本发明采用以下技术方案:
一种瑞马唑仑中间体的制备方法,所述制备方法的反应方程式为:
其中,R代表H、卤素或C1-C5的烷基;X代表H或卤素;
所述制备方法包括步骤:
(1)将式A所示化合物与式Ⅱ所示化合物混合反应,得到式B所示化合物;
(2)所述式B所示化合物加入溶剂中溶解,之后加碱,反应制得式C所示化合物。
作为本发明一种实施方案,所述R代表H、氯、溴、碘、甲基或乙基。优选地,所述R代表H、溴或甲基。
作为本发明一种实施方案,所述X代表H、氯、溴或碘。优选地,所述X代表H或氯。
作为本发明一种实施方案,所述步骤(1)中,反应时还添加正丁基锂。
作为本发明一种实施方案,所述步骤(1)中,式A所示化合物与式Ⅱ所示化合物的物料摩尔比为:式A所示化合物:式Ⅱ所示化合物=1:(1.5~2.5)。优选地,式A所示化合物:式Ⅱ所示化合物=1:(1.5~2.0)。
作为本发明一种实施方案,式A所示化合物与正丁基锂的物料摩尔比为:式A所示化合物:正丁基锂=1:(2.0~3.0)。优选地,式A所示化合物:正丁基锂=1:(2.0~2.5)。
作为本发明一种实施方案,所述步骤(1)中,反应溶剂为四氢呋喃。
作为本发明一种实施方案,所述步骤(1)中,反应温度为-15℃~10℃,优选为-10℃~0℃。
作为本发明一种实施方案,所述步骤(2)中,所述式B所示化合物与所述碱的物料摩尔比为1:(0.1~0.8),优选为1:(0.4~0.6)。
作为本发明一种实施方案,所述碱选自氢氧化钾、氢氧化钠、碳酸钠、碳酸氢钠中的至少一种。优选地,所述碱为碳酸钠。
作为本发明一种实施方案,所述步骤(2)中,反应温度为115℃~140℃。
作为本发明一种实施方案,所述步骤(2)中,反应溶剂为非质子型溶剂,优选所述溶剂为DMF(N,N-二甲基甲酰胺)、DMSO(二甲基亚砜)、DMAC(N,N-二甲基乙酰胺)、NMP(N-甲基吡咯烷酮)中的任一种。进一步优选地,所述溶剂为DMF。
本发明提供的瑞马唑仑中间体的制备方法,合成路线简短,原料便宜,操作简单,易于工业化生产;并且得到的目标化合物(式C所示)纯度高,其HPLC纯度大于99%。
具体实施方式
下面通过实施例,对本发明的技术方案进行详细说明。
以下实施例采用的原料,未作特殊说明的,均通过购买获得。
实施例1
本实施例提供了一种如下所示化合物的制备方法:
反应方程式为:
制备过程如下:
氮气保护下,在三口瓶中加入0.2mol的正丁基锂,维持温度在-60℃~-50℃之间;之后加入2-溴吡啶(31.6g,0.2mol),搅拌反应,通过HPLC监测,反应至体系中2-溴吡啶含量低于1%,然后向反应体系中添加靛红(14.7g,0.1mol)的四氢呋喃溶液,加完后自然升温至-5℃,并维持温度在-10℃~0℃范围内进行反应,通过HPLC监测,待靛红反应物消失,反应结束。
将反应液倒入饱和氯化铵水溶液(180mL)中淬灭,控制温度在20℃下进行淬灭反应;淬灭后的水相用乙酸乙酯(200mL)萃取,有机相用饱和氯化钠水溶液(400mL×3)洗涤,所得萃取液和洗涤后的有机相合并,浓缩,之后柱层析提纯得目标化合物3-羟基-3-(吡啶-2-基)吲哚-2-酮,共20.7g,纯度为98%。
在单口瓶中加入30ml的DMF、Na2CO3(0.53g,0.005mol)和化合物3-羟基-3-(吡啶-2-基)吲哚-2-酮(2.3g,0.01mol),之后维持温度在125℃~135℃下反应,TLC监测,反应至化合物3-羟基-3-(吡啶-2-基)吲哚-2-酮消失,反应结束。
反应结束后,将反应液降至室温,然后加入饱和食盐水(20mL),再加入乙酸乙酯萃取(20mL),水相之后再用乙酸乙酯(15mL×2)萃取,萃取液合并后干燥,浓缩,柱层析得到目标化合物(2-氨基苯基)-(吡啶-2-基)-甲酮固体,共1.8g,纯度为99%。
目标化合物的鉴定数据为:1H NMR(δ6-DMSO,300MHz):δ=8.75(d,J=8.2Hz,1H),8.10(m,1H),8.01(d,1H),7.94(m,1H),7.82(m,1H),7.05(m,1H),6.99(m,1H),6.66(d,1H),6.27(s,2H);
13CNMR(100MHz,CDCl3):δ=199.25,151.07,140.25,134.74,134.38,131.19,129.26,128.23,118.32,117.13,115.66;
MS(ESI)C12H10N2O[M+H]+199.8,found 198.0。
实施例2
本实施例提供了一种如下所示化合物的制备方法:
反应方程式为:
制备过程如下:
氮气保护下,在三口瓶中加入0.2mol的正丁基锂,维持温度在-60℃~-50℃之间;之后加入2-溴-4-氯吡啶(38.4g,0.2mol),搅拌反应,通过HPLC监测,反应至体系中2-溴-4-氯吡啶的含量低于1%,然后向反应体系中添加靛红(14.7g,0.1mol)的四氢呋喃溶液,加完后自然升温至-7℃,并维持温度在-10℃~0℃范围内进行反应,通过HPLC监测,待靛红反应物消失,反应结束。
将反应液倒入饱和氯化铵水溶液(270mL)中淬灭,控制温度在20℃下进行淬灭反应;淬灭后的水相用乙酸乙酯(300mL)萃取,有机相用饱和氯化钠水溶液(400mL×3)洗涤,所得萃取液和洗涤后的有机相合并,浓缩,之后柱层析提纯得化合物3-(4-氯吡啶-2-基)-3-羟基吲哚-2-酮,共24.5g,纯度为97%。
在单口瓶中加入30ml的DMF、Na2CO3(0.53g,0.005mol)和化合物3-(4-氯吡啶-2-基)-3-羟基吲哚-2-酮(2.6g,0.01mol),之后维持温度在120℃~130℃下反应,TLC监测,反应至化合物3-(4-氯吡啶-2-基)-3-羟基吲哚-2-酮消失,反应结束。
反应结束后,将反应液降至室温,然后加入饱和食盐水(20mL),再加入乙酸乙酯萃取(20mL),水相之后再用乙酸乙酯(15mL×2)萃取,萃取液合并后干燥,浓缩,柱层析提纯得到目标化合物(2-氨基苯基)-(4-氯吡啶-2-基)-甲酮固体,共2.1g,纯度为99%。
目标化合物的鉴定数据为:1HNMR(δ6-DMSO,300MHz):δ=8.68(d,J=8.2Hz,1H),8.05(dd,J=8.9,Hz,1H),8.01(d,J=8.2Hz,1H)7.05(m,1H),6.99(m,1H),6.66(d,1H),6.27(s,2H);
13CNMR(δ6-DMSO,300MHz):δ=198.03,149.38,139.33,134.20,133.27,131.54,129.12,128.34,119.98,118.83,118.47;
MS(ESI)C12H9ClN2O[M+H]+233.04,found 232。
实施例3
本实施例提供了一种如下所示化合物的制备方法:
反应方程式为:
制备过程如下:
氮气保护下,在三口瓶中加入0.2mol的正丁基锂,维持温度在-60℃~-50℃之间;之后加入2-溴吡啶(31.6g,0.2mol),搅拌反应,通过HPLC监测,反应至体系中2-溴吡啶含量低于1%,然后向反应体系中添加5-甲基靛红(16.1g,0.1mol)的四氢呋喃溶液,加完后自然升温至-4℃,并维持温度在-10℃~0℃范围内进行反应,通过HPLC监测,待5-甲基靛红反应物消失,反应结束。
将反应液倒入饱和氯化铵水溶液(180mL)中淬灭,控制温度在20℃下进行淬灭反应;淬灭后的水相用乙酸乙酯(200mL)萃取,有机相用饱和氯化钠水溶液(400mL×3)洗涤,所得萃取液和洗涤后的有机相合并,浓缩,之后柱层析提纯得化合物3-羟基-5-甲基-3-(吡啶-2-基)吲哚-2-酮,共22.1g,纯度为99%。
在单口瓶中加入30ml的DMF、Na2CO3(0.53g,0.005mol)和化合物3-羟基-5-甲基-3-(吡啶-2-基)吲哚-2-酮(2.4g,0.01mol),之后维持温度在125℃~135℃下反应,TLC监测,反应至化合物3-羟基-5-甲基-3-(吡啶-2-基)吲哚-2-酮消失,反应结束。
反应结束后,将反应液降至室温,然后加入饱和食盐水(20mL),再加入乙酸乙酯萃取(20mL),水相之后再用乙酸乙酯(15mL×2)萃取,萃取液合并后干燥,浓缩,柱层析提纯,得到目标化合物(2-氨基-5-甲基苯基)-(吡啶-2-基)-甲酮固体,共1.9g,纯度为99%。
目标化合物的鉴定数据为:1H NMR(δ6-DMSO,300MHz):δ=8.75(d,J=8.2Hz,1H),8.10(m,1H),7.94(d,J=8.2Hz,1H),7.83(s,1H),7.75(m,1H),7.24(d,J=8.4Hz,1H),6.86(s,1H),6.27(s,2H),2.17(s,3H);
13CNMR(δ6-DMSO,300MHz):δ=199.21,148.90,140.72,135.53,134.21,131.15,129.27,128.22,124.60,118.40,117.28,20.45;
MS(ESI)C13H12N2O[M+H]+213.2,found 212.0。
实施例4
本实施例提供了一种如下所示化合物的制备方法:
反应方程式为:
制备过程如下:
氮气保护下,在三口瓶中加入0.2mol的正丁基锂,维持温度在-60℃~-50℃;之后加入2-溴-4-氯吡啶(38.4g,0.2mol),搅拌反应,通过HPLC监测,反应至体系中2-溴-4-氯吡啶的含量低于1%,然后向反应体系中添加5-甲基靛红(16.1g,0.1mol)的四氢呋喃溶液,加完后自然升温至-1℃,并维持温度在-10℃~0℃范围内进行反应,通过HPLC监测,待5-甲基靛红反应物消失,反应结束。
将反应液倒入饱和氯化铵水溶液(180mL)中淬灭,控制温度在20℃下进行淬灭反应;淬灭后的水相用乙酸乙酯(200mL)萃取,有机相用饱和氯化钠水溶液(400mL×3)洗涤,所得萃取液和洗涤后的有机相合并,浓缩,之后柱层析提纯,得化合物3-(4-氯吡啶-2-基)-3-羟基-5-甲基吲哚啉-2-酮,共25.2g,纯度为99%。
在单口瓶中加入30ml的DMF、Na2CO3(0.53g,0.005mol)和化合物3-(4-氯吡啶-2-基)-3-羟基-5-甲基吲哚啉-2-酮(2.7g,0.01mol),之后维持温度在125℃~135℃下反应,TLC监测,反应至化合物3-(4-氯吡啶-2-基)-3-羟基-5-甲基吲哚啉-2-酮消失,反应结束。
反应结束后,将反应液降至室温,然后加入饱和食盐水(20mL),再加入乙酸乙酯萃取(20mL),水相之后再用乙酸乙酯(15mL×2)萃取,萃取液合并后干燥,浓缩,柱层析提纯得到目标化合物(2-氨基-5-甲基苯基)-(4-氯吡啶-2-基)-甲酮固体,共2.3g,纯度为99%。
目标化合物的鉴定数据为:1H NMR(δ6-DMSO,300MHz):δ=8.68(d,J=8.2Hz,1H),8.05(d,J=8.2,Hz,1H),7.83(s,1H),7.82(m,1H),7.24(d,J=8.4Hz,1H),6.86(s,1H),6.27(s,2H),2.17(s,3H);
13CNMR(δ6-DMSO,300MHz):δ=199.21,148.90,140.72,135.53,134.21,131.15,129.27,128.22,124.60,118.40,117.28,20.45;
MS(ESI)C13H11ClN2O[M+H]+247.06,found 246。
实施例5
本实施例提供了一种如下所示化合物的制备方法:
反应方程式为:
制备过程如下:
氮气保护下,在三口瓶中加入0.2mol的正丁基锂,维持温度在-60℃~-50℃之间;之后加入2-溴吡啶(31.6g,0.2mol),搅拌反应,通过HPLC监测,反应至体系中2-溴吡啶含量低于1%,然后向反应体系中添加5-溴靛红(22.6g,0.1mol)的四氢呋喃溶液,加完后自然升温至-4℃,并维持温度在-10℃~0℃范围内进行反应,通过HPLC监测,待5-溴靛红反应物消失,反应结束。
将反应液倒入饱和氯化铵水溶液(180mL)中淬灭,控制温度在20℃下进行淬灭反应;淬灭后的水相用乙酸乙酯(200mL)萃取,有机相用饱和氯化钠水溶液(400mL×3)洗涤,所得萃取液和洗涤后的有机相合并,浓缩,之后柱层析提纯,得化合物5-溴-3-羟基-3-(吡啶-2-基)吲哚-2-酮,共28.7g,纯度为98%。
在单口瓶中加入30ml的DMF、Na2CO3(0.53g,0.005mol)和化合物5-溴-3-羟基-3-(吡啶-2-基)吲哚-2-酮(3.1g,0.01mol),之后维持温度在125℃~135℃下反应,TLC监测,反应至化合物5-溴-3-羟基-3-(吡啶-2-基)吲哚-2-酮消失,反应结束。
反应结束后,将反应液降至室温,然后加入饱和食盐水(20mL),再加入乙酸乙酯萃取(20mL),水相之后再用乙酸乙酯(15mL×2)萃取,萃取液合并后干燥,浓缩,柱层析提纯,得到目标化合物(2-氨基-5-溴苯基)-(吡啶-2-基)-甲酮固体,共2.4g,纯度为99%。
目标化合物的鉴定数据为:1H NMR(δ6-DMSO,300MHz):δ=8.68(d,J=8.2Hz,1H),8.05(d,J=8.2,Hz,1H),7.83(s,1H),7.82(m,1H),7.24(d,J=8.4Hz,1H),6.86(s,1H),6.27(s,2H);
13CNMR(δ6-DMSO,300MHz):δ=199.21,148.90,140.72,135.53,134.21,131.15,129.27,128.22,124.60,118.40,117.28,20.45;
MS(ESI)C12H9BrN2O[M+H]+277.06,found 276。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等效变换,或直接或间接运用在其他相关的技术领域,均包括在本发明的专利保护范围内。
Claims (10)
1.一种瑞马唑仑中间体的制备方法,其特征在于,所述制备方法的反应方程式为:
其中,R代表H、卤素或C1-C5的烷基;X代表H或卤素;
所述制备方法包括步骤:
(1)将式A所示化合物与式Ⅱ所示化合物混合反应,得到式B所示化合物;
(2)所述式B所示化合物加入溶剂中溶解,之后加碱,反应制得式C所示化合物。
2.根据权利要求1所述的制备方法,其特征在于,所述R代表H、氯、溴、碘、甲基或乙基;优选地,所述R代表H、溴或甲基。
3.根据权利要求1或2所述的制备方法,其特征在于,所述X代表H、氯、溴或碘,优选地,所述X代表H或氯。
4.根据权利要求1-3任一项所述的制备方法,其特征在于,所述步骤(1)中,反应时还添加正丁基锂。
5.根据权利要求4所述的制备方法,其特征在于,所述步骤(1)中,式A所示化合物与式Ⅱ所示化合物的物料摩尔比为:式A所示化合物:式Ⅱ所示化合物=1:(1.5~2.5),优选地,式A所示化合物:式Ⅱ所示化合物=1:(1.5~2.0);和/或,
式A所示化合物与正丁基锂的物料摩尔比为:式A所示化合物:正丁基锂=1:(2.0~3.0),优选地,式A所示化合物:正丁基锂=1:(2.0~2.5)。
6.根据权利要求5所述的制备方法,其特征在于,所述步骤(1)中,反应溶剂为四氢呋喃。
7.根据权利要求1-6任一项所述的制备方法,其特征在于,所述步骤(1)中,反应温度为-15℃~10℃,优选为-10℃~0℃。
8.根据权利要求1-7任一项所述的制备方法,其特征在于,所述步骤(2)中,所述式B所示化合物与所述碱的物料摩尔比为1:(0.1~0.8),优选为1:(0.4~0.6);和/或,
所述碱选自氢氧化钾、氢氧化钠、碳酸钠、碳酸氢钠中的至少一种。
9.根据权利要求8所述的制备方法,其特征在于,所述步骤(2)中,反应温度为115℃~140℃。
10.根据权利要求8或9所述的制备方法,其特征在于,所述步骤(2)中,反应溶剂为非质子型溶剂,优选所述溶剂为DMF、DMSO、DMAC、NMP中的任一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311400526.4A CN117447393A (zh) | 2023-10-26 | 2023-10-26 | 一种瑞马唑仑中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311400526.4A CN117447393A (zh) | 2023-10-26 | 2023-10-26 | 一种瑞马唑仑中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117447393A true CN117447393A (zh) | 2024-01-26 |
Family
ID=89595879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311400526.4A Pending CN117447393A (zh) | 2023-10-26 | 2023-10-26 | 一种瑞马唑仑中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117447393A (zh) |
-
2023
- 2023-10-26 CN CN202311400526.4A patent/CN117447393A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1797037T3 (en) | PROCESS FOR THE PREPARATION OF 4- {4 - [({[4-chloro-3- (trifluoromethyl) phenyl] AMINO} CARBONYL) AMINO] PHENYOXY} N-methylpyridine-2-carboxamide | |
KR100423627B1 (ko) | 캄프토테신유도체(씨피티-11)및관련화합물의제조를위한신규중간체및제조방법 | |
JP6061158B2 (ja) | 6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミド、またはそれの薬学的に許容される塩の合成中間体およびその使用 | |
JP5934182B2 (ja) | 4−{4−[({[4−クロロ−3−(トリフルオロメチル)フェニル]アミノ}カルボニル)アミノ]−3−フルオロフェノキシ}−n−メチルピリジン−2−カルボキサミド、その塩及び一水和物の製造方法 | |
TW201922757A (zh) | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 | |
TWI592401B (zh) | 用於製備4-胺基-3-氯-5-氟-6-(經取代的)吡啶甲酸酯的方法(一) | |
JP2002338516A (ja) | 2−ハロゲン化安息香酸類の製造方法 | |
JP5656952B2 (ja) | ピペラジン誘導体蓚酸塩結晶 | |
CN108069869B (zh) | 一种Apalutamide的制备方法及其中间体 | |
BR102012001633A2 (pt) | Processo para a preparação de 4-amino-5-fluoro-3-halo-6(substituído) picolinatos | |
JP2014516072A (ja) | アピキサバン製造方法 | |
JPH0395144A (ja) | アミノフェノール誘導体の製造方法 | |
KR101420892B1 (ko) | 이마티닙 및 그들의 중간체 및 그 제조방법 | |
CN112679420B (zh) | 一种2,5-二溴吡啶的制备方法 | |
CN111315742A (zh) | 制备氨基嘧啶衍生物的改善方法 | |
CN105198821B (zh) | 洛昔替尼的制备方法 | |
EP3265439A1 (en) | Process for preparing 3-chloro-2-vinylphenylsulfonates | |
WO2014024950A1 (ja) | 1,4-ベンゾオキサジン化合物の製法 | |
DE69920045T2 (de) | Verfahren zur herstellung von n6-substituierten deaza-adenosinderivaten | |
JP6705458B2 (ja) | トリアゾール化合物の製造方法 | |
CN117447393A (zh) | 一种瑞马唑仑中间体的制备方法 | |
JPH0699396B2 (ja) | 新規オキサゾロピリジン誘導体 | |
JP5555773B2 (ja) | モンテルカストナトリウム中間体の合成方法 | |
CN102731368A (zh) | 一种5,5-二氟-3-取代哌啶衍生物的制备方法 | |
CN110003101B (zh) | 一种阿帕替尼中间体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |